CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer
NCT ID: NCT03916367
Last Updated: 2019-05-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
39 participants
OBSERVATIONAL
2010-12-15
2019-02-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Application of 4DCT-Based Pulmonary Ventilation Imaging in Lung Cancer Radiotherapy
NCT07312682
PCI for Patients With ES-SCLC After RCT:a Prospective Randomized Study
NCT04535739
Thoracic Re-irradiation For Locoregionally Recurrent Non-small Cell Lung Cancer
NCT04275687
Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
NCT07166003
Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors
NCT05834413
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Early Stage Lung Cancer
The patients with early stage non-small cell lung cancer who were treated with CT-guided radioactive iodine-125 seeds implantation during December 2010 to December 2018.
CT-guided Radioactive I-125 Seeds Implantation
The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
CT-guided Radioactive I-125 Seeds Implantation
The radioactive Iodine-125 seed can release low dose of irradiation persistently which kills tumors cell and causes less damage to normal tissue at the same time. The treatment was performed under CT monitoring.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* UICC (Union for International Cancer Control) stage was T1-3N0M0 (stage Ia-IIb)
* inoperable and CT-guided radioactive iodine-125 seeds brachytherapy was used as the initial treatment without external beam radiotherapy
Exclusion Criteria
* case information and/or follow-up information was unavailable
18 Years
85 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking University Third Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Junjie Wang, M.D. Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Department of Radiation Oncology, Peking University Third Hospital
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CNRBG-81532-ESNSCLC-RISI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.